申请人:Parthasaradhi Reddy Bandi
公开号:US20100137613A1
公开(公告)日:2010-06-03
The present invention provides an improved and commercially viable process for preparation of eprosartan and its pharmaceutically acceptable acid addition salts thereof in high purity and in high yield. Thus, for example, methyl 4-[[2-butyl-5-formyl-1 H-imidazol-1-yl]methyl]benzoate is reacted with ethyl 2-carboxy-3-(2-thienyl)propionate in the presence of a base, such as piperidine or piperidinium propionate in propionic acid, in cyclohexane solvent to give ethyl (αE)-α-[(2-n-butyl-1-[(4-(methoxy-carbonyl) phenyl]methyl]-1 H-imidazol-5-yl]methylene-2-thiophene propionate substantially free of decarboxylate impurity namely, ethyl 3-(2-thienyl)propionate, which is then subjected to base hydrolysis followed by treatment with methanesulfonic acid to obtain eprosartan mesylate in high purity and in high yield.
本发明提供了一种改进的、商业上可行的方法,用于制备高纯度和高产率的依普罗沙坦及其药用盐酸盐。例如,将甲基4-[[2-丁基-5-甲酰基-1H-咪唑-1-基]甲基]苯甲酸酯与乙酸乙酯2-羧基-3-(2-噻吩基)丙酸酯在碱的存在下反应,例如在丙酸中的哌啶或哌啶丙酸盐的存在下,在环己烷溶剂中反应,得到乙酸乙酯(αE)-α-[(2-正丁基-1-[(4-甲氧羰基)苯基]甲基)-1H-咪唑-5-基]亚甲基-2-噻吩丙酸酯,其基本上不含脱羧杂质,即乙酸乙酯3-(2-噻吩基)丙酸酯,然后进行碱水解,随后用甲磺酸处理,得到高纯度和高产率的依普罗沙坦甲磺酸盐。